CN110354265A - 用于肌萎缩性侧索硬化的治疗剂 - Google Patents

用于肌萎缩性侧索硬化的治疗剂 Download PDF

Info

Publication number
CN110354265A
CN110354265A CN201910808882.7A CN201910808882A CN110354265A CN 110354265 A CN110354265 A CN 110354265A CN 201910808882 A CN201910808882 A CN 201910808882A CN 110354265 A CN110354265 A CN 110354265A
Authority
CN
China
Prior art keywords
amino acid
ruilin
therapeutic agent
acid residue
lateral sclerosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910808882.7A
Other languages
English (en)
Chinese (zh)
Inventor
松尾刚
村山宣人
古谷真优美
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of CN110354265A publication Critical patent/CN110354265A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cell Biology (AREA)
CN201910808882.7A 2012-10-24 2013-10-23 用于肌萎缩性侧索硬化的治疗剂 Pending CN110354265A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012234300 2012-10-24
JP2012-234300 2012-10-24
CN201380066625.1A CN104853778A (zh) 2012-10-24 2013-10-23 用于肌萎缩性侧索硬化的治疗剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380066625.1A Division CN104853778A (zh) 2012-10-24 2013-10-23 用于肌萎缩性侧索硬化的治疗剂

Publications (1)

Publication Number Publication Date
CN110354265A true CN110354265A (zh) 2019-10-22

Family

ID=50544716

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910808882.7A Pending CN110354265A (zh) 2012-10-24 2013-10-23 用于肌萎缩性侧索硬化的治疗剂
CN201380066625.1A Pending CN104853778A (zh) 2012-10-24 2013-10-23 用于肌萎缩性侧索硬化的治疗剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380066625.1A Pending CN104853778A (zh) 2012-10-24 2013-10-23 用于肌萎缩性侧索硬化的治疗剂

Country Status (11)

Country Link
US (1) US20150265680A1 (enExample)
EP (1) EP2913063B1 (enExample)
JP (1) JP6262661B2 (enExample)
KR (3) KR20150070180A (enExample)
CN (2) CN110354265A (enExample)
AU (1) AU2013335678B9 (enExample)
BR (1) BR112015009107A2 (enExample)
CA (1) CA2889499C (enExample)
IN (1) IN2015DN04172A (enExample)
RU (1) RU2655811C2 (enExample)
WO (1) WO2014065341A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016077498A1 (en) 2014-11-12 2016-05-19 Lyric Pharmaceuticals Inc. Treatment of enteral feeding intolerance
WO2017083882A1 (en) * 2015-11-11 2017-05-18 Lyric Pharmaceuticals Inc. Treatment of enteral feeding intolerance and other conditions using ulimorelin analogs
KR20210102294A (ko) * 2018-12-06 2021-08-19 바이오젠 엠에이 인코포레이티드 근위축성 측삭 경화증에서 치료요법적 중재를 안내하기 위한 신경필라멘트 단백질
EP4611737A1 (en) * 2022-11-03 2025-09-10 Lumos Pharma, Inc. Compactable oral formulations of ibutamoren

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668254A (en) 1990-05-11 1997-09-16 Romano Deghenghi D-2-alkyl-tryptophan and peptides containing same
US5663146A (en) 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
US5578593A (en) 1992-12-11 1996-11-26 Merck & Co., Inc. Spiro piperidines and homologs promote release of growth hormone
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
US6576656B1 (en) 1998-08-20 2003-06-10 Sumitomo Pharmaceuticals Co., Ltd. Oxindole derivative
PT1795598E (pt) * 1999-07-23 2010-01-05 Kenji Kangawa Novos péptidos
UA73530C2 (uk) 1999-11-10 2005-08-15 Ново Нордіск А/С Сполука з властивостями вивільнювати гормон росту
EP1258250B1 (en) * 1999-12-28 2005-09-14 Kaken Pharmaceutical Co., Ltd. Nerve protective drugs
CA2407659C (en) 2000-06-13 2010-11-09 Zentaris Ag Growth hormone secretagogues
BRPI0306644B8 (pt) 2002-04-11 2021-05-25 Asubio Pharma Co Ltd método para produzir um peptídeo modificado
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
JP2005239712A (ja) 2004-01-30 2005-09-08 Kaken Pharmaceut Co Ltd 神経突起伸展剤
WO2006079077A2 (en) * 2005-01-20 2006-07-27 Acadia Pharmaceuticals Inc. Use of diltiazem or analogs thereof as modulators of ghrelin receptor
US7829589B2 (en) 2005-06-10 2010-11-09 Elixir Pharmaceuticals, Inc. Sulfonamide compounds and uses thereof
WO2007046347A1 (ja) * 2005-10-18 2007-04-26 Ono Pharmaceutical Co., Ltd. 筋萎縮性側索硬化症患者の運動神経保護用医薬
ES2596885T3 (es) 2006-06-07 2017-01-12 Genzyme Corporation Terapia génica para esclerosis lateral amiotrófica y otros trastornos de la medula espinal
JP2008127377A (ja) 2006-11-24 2008-06-05 Jichi Medical Univ Ｇｈｓ−ｒ作動薬を含有してなるメタボリックシンドローム又は高血圧症の予防・治療剤。
KR100946084B1 (ko) 2008-03-27 2010-03-10 주식회사 하이닉스반도체 반도체 소자의 수직형 트랜지스터 및 그 형성방법
MX2010010495A (es) * 2008-04-03 2010-10-15 Hoffmann La Roche Uso de variantes del factor de crecimiento similar a la insulina (igf-i) pegiladas para el tratamiento de trastornos neuromusculares.

Also Published As

Publication number Publication date
EP2913063B1 (en) 2019-09-11
JPWO2014065341A1 (ja) 2016-09-08
AU2013335678B9 (en) 2024-12-12
KR20200108494A (ko) 2020-09-18
IN2015DN04172A (enExample) 2015-10-16
BR112015009107A2 (pt) 2017-11-14
WO2014065341A1 (ja) 2014-05-01
KR102499918B1 (ko) 2023-02-14
JP6262661B2 (ja) 2018-01-17
AU2013335678B2 (en) 2017-10-26
CA2889499A1 (en) 2014-05-01
CA2889499C (en) 2019-09-10
CN104853778A (zh) 2015-08-19
HK1214152A1 (en) 2016-07-22
EP2913063A1 (en) 2015-09-02
KR20220051418A (ko) 2022-04-26
RU2015119472A (ru) 2016-12-20
KR20150070180A (ko) 2015-06-24
US20150265680A1 (en) 2015-09-24
EP2913063A4 (en) 2016-07-20
RU2655811C2 (ru) 2018-05-29
AU2013335678A1 (en) 2015-05-21

Similar Documents

Publication Publication Date Title
JP6552117B2 (ja) 敗血症の予防治療剤
KR101802411B1 (ko) Ｆａｍ１９ａ５ 단백질을 포함하는 비만 예방 또는 치료용 조성물 및 이를 이용한 비만 치료제의 스크리닝 방법
EP2823823B1 (en) Polypeptides for the preparation of drugs for treatment or prevention of rheumatoid arthritis
KR101661332B1 (ko) 글루카곤 유사 펩타이드-1 수용체 항진제를 포함하는 근감소증 치료용 약학 조성물
CN111417647A (zh) 新型senolytic肽
WO2021027704A1 (zh) 多肽或其衍生物的应用
CN110354265A (zh) 用于肌萎缩性侧索硬化的治疗剂
KR20200038408A (ko) IF1 (ATPase inhibitory factor 1)을 유효성분으로 함유하는 근감소증의 예방 또는 치료용 약학 조성물
US11820837B2 (en) Modified peptides and associated methods of use
WO2019103660A1 (en) Method of multiple sclerosis treatment (variants)
JP2007538017A (ja) 胃腸疾患の治療のためのｐｐｙ含有組成物
EP4516802A1 (en) Novel anti-inflammatory peptide and use thereof
KR20180027924A (ko) 글루카곤 유사 펩타이드-1(glp-1), glp-1 유래 펩타이드, 또는 glp-1 분해 억제제를 포함하는 근감소증 또는 근위축증 치료용 약학 조성물
KR20230160219A (ko) Pd-184352를 유효성분으로 포함하는 sncg 과발현 질환의 예방 또는 치료용 약학적 조성물
US20080125360A1 (en) Composition Comprising Pyy for the Treatment of Gastrointestinal Disorders
HK1214152B (en) Therapeutic agent for use in treating amyotrophic lateral sclerosis
WO2025110141A1 (ja) 睡眠改善剤
KR20240041399A (ko) 항암 활성을 갖는 신규한 펩타이드 및 이의 용도
KR20250023259A (ko) 근육 감소 억제 효과를 갖는 갈색거저리 유충 단백 가수분해 펩타이드 조성물
WO2024061251A1 (zh) 一种4-tmap治疗或缓解抑郁症的用途
KR20240162456A (ko) Az-628을 유효성분으로 포함하는 sncg 과발현 질환의 예방 또는 개선용 건강기능 식품 조성물
JP2009107928A (ja) パウ・フェロから単離された新規化合物
KR20170121449A (ko) Ｃｒｉｆ１을 유효성분으로 포함하는 자가면역질환의 예방 또는 치료용 조성물
ITRM20070481A1 (it) "sequenza peptidica bioattiva da impiegare in sostituzione della calcitonina umana"

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination